Johnson & Johnson's Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) receives U.S. FDA priority review as potential first-in-class Egfr- and Met-targeted subcutaneous treatment for advanced head and neck cancer
JNJ•FDA priority review for Rybrevant Faspro
July 30 (Reuters) - Johnson & Johnson JNJ.N:
- Johnson & Johnson's Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) receives U.S. FDA priority review as potential first-in-class Egfr- and Met-targeted subcutaneous treatment for advanced head and neck cancer
Source text: ID:nPn7ptQPQa
Further company coverage: JNJ.N
